8 teams take part of this network in order to characterize the functional dialogue between tumor hepatocytes or intestine cells and immune cells and proceed to define how this crosstalk affects tumorigenesis in the course of disease progression
The network analyzes tumor heterogeneity in colon and liver tumors to elucidate the architecture and the interplay between sub-clonal and clonal tumor cell development and its relationship with the immune microenvironment. Whole genome sequencing and novel technologies that allow the analysis of single cells for their genomic and immune expression profiles are used in the network. These data will be integrated with the fine phenotypic characterization of tumor heterogeneity, taking into consideration the clinical context of the patients.
To better understand the relations between the tumor cells and their immune and parenchymal responses, the network selected relevant animal models to analyze interactions of tumor cells in various microenvironmental backgrounds. Cell/cell interactions is aimed to be performed in 2D and 3D culture using classical techniques and innovative microfluidic technology developed within the network.
The interplay between tumor cells and the microenvironment will be modeled mathematically using novel algorithms and concepts with in vivo data (human and mice) and in cellulo. This innovative research will provide a paradigm for an integrated translational approach in the field of liver and colon cancer care. Our final aim is to identify novel methods and algorithms to predict sensitivity and resistance to treatments useful for patients’ care.
HetCoLi aim at the understanding of the natural history of liver and colon cancer, taking into account the huge heterogeneity of the tumors and their interplay with immunity. This novel dimension of analysis should enable to change our view of the role of the immune surveillance of cancer and hopefully to propose therapeutic approaches that will cope with the enormous diversity of liver and colon tumors
This French program is organized by ITMO Cancer, in collaboration with ITMO BCDE (Cell Biology, Development and Evolution) and ITMO Technologies for Health of the National Alliance for Life Sciences and Health (AVIESAN) with the National Cancer Institute (INCA) and Inserm within the framework of the Cancer Plan. Operational management is entrusted to Inserm.
It was launch in order to develop a critical mass of resources and skills in order to conduct interdisciplinary research projects in the field of functional heterogeneity of cellular tumor relations in their ecosystem: the "HTE Program".